Teva Pharmaceutical Industries Spon Ads Each Rep 1 Ord Shs (TEVA) Stock
Global generic drug manufacturer with specialty medicines. Here's the price, business snapshot, and what's worth knowing about Teva Pharmaceutical Industries Spon Ads Each Rep 1 Ord Shs in August 2026.
Teva Pharmaceutical Industries Ltd (TEVA) is a global pharmaceutical company best known for its large generics business and select specialty medicines. With a market capitalisation near $22 billion, Teva supplies a broad range of off‑patent medicines alongside branded treatments in areas such as central nervous system disorders. The company has undergone significant restructuring in recent years to cut costs, manage debt and refocus R&D. Key investor considerations include pricing pressure in generics, patent cliffs for older products, ongoing litigation and the balance sheet after past acquisitions. At the same time, scale in manufacturing, a diversified product mix and potential upside from speciality drugs or successful pipeline assets can support recovery. Investors should weigh Teva’s income statement trends, cash generation, debt reduction progress and the regulatory environment. This is general information for educational purposes only and not personalised investment advice; stock prices can fall as well as rise.
Why It’s Moving
Teva is gaining on a stronger balance sheet, a promising pipeline, and a still-active legal backdrop.
- Moody’s upgraded Teva to investment grade on August 11, reinforcing confidence in the company’s turnaround and potentially lowering future financing costs.
- The FDA granted priority review for ecopipam, a pipeline therapy for pediatric Tourette syndrome, giving investors a new catalyst tied to Teva’s shift toward branded growth.
- Recent legal headlines, including the Humana trial dispute and a patent settlement with Aurinia, kept attention on Teva’s litigation overhang even as the stock traded near a 52-week high.
Teva is gaining on a stronger balance sheet, a promising pipeline, and a still-active legal backdrop.
- Moody’s upgraded Teva to investment grade on August 11, reinforcing confidence in the company’s turnaround and potentially lowering future financing costs.
- The FDA granted priority review for ecopipam, a pipeline therapy for pediatric Tourette syndrome, giving investors a new catalyst tied to Teva’s shift toward branded growth.
- Recent legal headlines, including the Humana trial dispute and a patent settlement with Aurinia, kept attention on Teva’s litigation overhang even as the stock traded near a 52-week high.
About This Stock
TEVA PHARMACEUTICAL INDUSTRIES SPON ADS EACH REP 1 ORD SHS
TEVA
Current Price
$37.38
Potential 12 Month Profit
-12.97%
Sector
Healthcare
Industry
Pharmaceuticals
Ticker
TEVA
Market Cap
$43.52B
Potential 12 Month Profit
-12.97%
Sector
Healthcare
Industry
Pharmaceuticals
Sixth Month Growth Performance
next-earnings-question
Teva’s next earnings date is expected on November 4, 2026, based on its typical reporting pattern and current estimates. The report should cover Q3 2026 results. This timing is consistent with Teva’s prior quarterly release cadence.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Teva's stock as it has potential to rise from its current price.
Financial Health
Teva is generating strong revenue and cash flow, indicating a solid financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Volume & Scale
Teva’s large manufacturing footprint drives cost advantages in generics, which can support margins — though pricing pressure and competition remain important caveats.
Speciality Pipeline Focus
Selective branded assets and R&D in areas like CNS could offer upside if successful, but development outcomes and regulatory hurdles create uncertainty.
Balance Sheet Watch
Investors often focus on debt reduction and cash flow recovery; improvements can strengthen prospects, while unresolved liabilities can limit flexibility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.